<DOC>
	<DOCNO>NCT00529932</DOCNO>
	<brief_summary>An international , multi-centre , double-blind , randomised , placebo-controlled clinical trial central core lab analyse determine safety intra-coronary infusion enrich CD133+ , bone marrow-derived , autologous progenitor cell patient 5-10 day acute percutaneous coronary revascularization ( primary PCI ) ST-segment elevation myocardial infarction ( STEMI ) .</brief_summary>
	<brief_title>A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Primary PCI acute STEMI 224 hour onset chest pain . STsegment elevation &gt; =2mm &gt; =3 adjacent lead . Presence severe hypokinesia and/or akinesia &gt; =2 adjacent segment echocardiogram 4872 hr primary PCI . Age 20 75 year . Pregnant lactating . Prior history myocardial infarction index event . Decompensated congestive heart failure . Preexistent LV dysfunction ( EF &lt; 45 % prior admission ) Cardiomyopathy . Previous cardiac surgery . Congenital heart disorder . Serum creatinine &gt; 200 Mmol/L . Presence permanent pacemaker implantable defibrillator . Contraindication bone marrow aspiration . History malignancy within 5 year except curatively treat basal cell carcinoma , squamous cell carcinoma and/or cervical carcinoma . Sustained inducible VT &gt; 48 hour post primary PCI . Three vessel coronary artery disease necessitate intervention within 4 month . Immune compromise include chronic human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . Presence chronic systemic inflammatory disorder . Previous autologous allogeneic bone marrow peripheral stem cell transplant prior solid organ transplantation . Low hemoglobin , white blood cell , absolute neutrophil and/or platelet count . Any condition associate life expectancy le 6 month . Participation unrelated research involve investigational pharmacological agent ( ) 30 day plan dose . Current alcohol drug abuse . Inability provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Celltherapy</keyword>
	<keyword>Bone Marrow</keyword>
</DOC>